Medicine and Dentistry
Adverse Event
17%
Anticarcinogen
5%
Biological Marker
41%
Biopsy
23%
Cancer Treatment
23%
Clinician
11%
Cohort Analysis
23%
Cytotechnology
23%
Diagnosis
23%
Disease Free Survival
11%
Diseases
23%
Drug Megadose
42%
Effusion
23%
Fluorodeoxyglucose F 18
23%
Health Care
23%
Immune Checkpoint Inhibitor
17%
Immunohistochemistry
27%
Immunotherapy
27%
Ipilimumab
23%
Logistic Regression Analysis
11%
Lung Cancer
71%
Malignant Neoplasm
11%
Mesothelioma
23%
Minimal Residual Disease
11%
Multivariate Analysis
22%
Neoplasm
27%
Nitric Oxide
23%
Nivolumab
23%
Non Small Cell Lung Cancer
99%
Oncology
11%
Overall Survival
26%
Pemetrexed
23%
Pleura Mesothelioma
47%
Positron Emission Tomography-Computed Tomography
23%
Prognosis
23%
Proportional Hazards Model
10%
Quality of Life
11%
Radiation Pneumonia
47%
Radiation Therapy
42%
Radiation-Induced Lung Injury
23%
Recurrent Disease
11%
Sarcomatoid
6%
Shared Decision Making
7%
Short Term Memory
11%
Supportive Care
9%
Surgery
5%
Systemic Therapy
9%
Telomerase
23%
Therapy Delay
23%
Venous Thromboembolism
23%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
5%
Adverse Event
14%
Anticarcinogen
5%
Biological Marker
38%
Chemotherapy
94%
Cisplatin
15%
Cohort Study
23%
Disease
23%
Disease Free Survival
7%
Diseases
11%
Enzyme Defect
5%
First-Line Chemotherapy
5%
Fluorodeoxyglucose F 18
23%
Immune Checkpoint Inhibitor
17%
Immunotherapy
28%
Ipilimumab
47%
Liver Enzyme
5%
Lung Cancer
71%
Malignant Neoplasm
31%
microRNA
7%
Minimal Residual Disease
11%
Neoplasm
32%
Nivolumab
47%
Non Small Cell Lung Cancer
100%
Open-Label Trial
5%
Overall Survival
22%
Pemetrexed
23%
Pleura Mesothelioma
71%
Polyethylene Terephthalate
23%
Prognosis
23%
Progression Free Survival
23%
Radiation Pneumonia
23%
Rash
5%
Recurrent Disease
7%
Solid Malignant Neoplasm
5%
Systemic Treatment
10%
Telomerase
47%
Tree
23%
Venous Thromboembolism
23%
Keyphrases
18F-FDG PET-CT
23%
Blinded Independent Central Review
17%
Cancer Toxicity
23%
Clinical Benefit
5%
Dose Reduction
5%
Dynamic Risk Assessment
23%
Epidermal Growth Factor Receptor
23%
High-dose Radiation Therapy
18%
Ipilimumab
23%
Liver Enzyme Abnormality
5%
Lung Adenocarcinoma
5%
Lung Growth
5%
Malignant Pleural Mesothelioma
23%
Metabolic Tumor Volume
14%
Metastatic Lung Cancer
23%
Multivariate Analysis
9%
NIPU
9%
Nivolumab
23%
Outcome Prediction
23%
Phase II Randomized Trial
23%
Prediction Method
23%
Radiation Pneumonitis
23%
Radiation-induced Lung Injury
23%
Radiological Response
5%
Rash
5%
Reactive Mesothelial Proliferation
13%
Recommended Dose
5%
Sensitizing mutations
23%
Standardized Uptake Value
9%
SUVmax
9%
SUVpeak
23%
Telomerase
23%
Time-dependent Toxicity
23%
Tolerable Side Effects
5%
Total Lesion Glycolysis
9%
WHO Performance Status
5%
